Prestige Consumer Results During COVID Show Success From Shifting Entirely To Health Care
Executive Summary
Sales growth for OTC drug brands during latest quarter contribute to Prestige increasing its full-year guidance for FY2022, which ends on 31 March, for revenues growing around 9% to between $1.075bn and $1.08bn.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare
Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.
Prestige Consumer Feels ‘5-Ounce Hammer' From Pandemic Headwinds
Prestige hasn’t totally escaped supply chain disruptions caused by shutdowns during the pandemic but it’s relieved to report a smaller impact than most consumer-packaged goods marketers. Slower cough/cold OTC sales also don’t slow its results.